Title

Safety and efficacy of durvalumab with R-CHOP or R

Authors

Grzegorz S Nowakowski
Wolfgang Willenbacher
Richard Greil
Thomas S Larsen
Krish Patel, Swedish Cancer Institute Hematology and Oncology Department, Center for Blood Disorders and Stem Cell Transplantation, Seattle, WA, USAFollow
Ulrich Jäger
Robert F Manges
Lorenz Trümper
Hele Everaus
Nagesh Kalakonda
Peter Brown
Judit Meszaros Jørgensen
David Cunningham
Justine Dell'Aringa
Brian Fox
Neus Domper Rubio
Nurgul Kilavuz
Marie-Laure Casadebaig
Oliver Manzke
Javier Munoz

Document Type

Article

Publication Date

11-19-2021

Publication Title

International journal of hematology

Keywords

washington; seattle; swedish cancer; Diffuse large B-cell lymphoma; Durvalumab; High risk; R-CHOP

Abstract

Patients with high-risk diffuse large B-cell lymphoma (DLBCL) have poor outcomes following first-line cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab (R-CHOP). Evidence shows chemotherapy and immune checkpoint blockade can increase antitumor efficacy. This study investigated durvalumab, a programmed death-ligand 1 inhibitor, combined with R-CHOP or lenalidomide + R-CHOP (R

Clinical Institute

Cancer

Department

Oncology

Recommended Citation

Nowakowski, Grzegorz S; Willenbacher, Wolfgang; Greil, Richard; Larsen, Thomas S; Patel, Krish; Jäger, Ulrich; Manges, Robert F; Trümper, Lorenz; Everaus, Hele; Kalakonda, Nagesh; Brown, Peter; Jørgensen, Judit Meszaros; Cunningham, David; Dell'Aringa, Justine; Fox, Brian; Rubio, Neus Domper; Kilavuz, Nurgul; Casadebaig, Marie-Laure; Manzke, Oliver; and Munoz, Javier, "Safety and efficacy of durvalumab with R-CHOP or R" (2021). Articles, Abstracts, and Reports. 5506.
https://digitalcommons.providence.org/publications/5506